Covid 19 Research using Clinical Trials (Home Page)
Convalescent Plasma TransfusionWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
Correlated MeSH Terms (5)
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
Currently, no effective treatments are available for the COVID-19 pandemic, which is related
to more than 70,000 deaths all over the world. Scientists and Researchers are working on many
aspects of treatment options for the development of vaccination and medication to combat this
life-threatening problem. Convalescent plasma from recovered COVID-19 patients contains
antibodies against COVID-19 which may be beneficial to severely sick COVID019 infected
patients. We have planned a randomized controlled trial to assess the efficacy of this
therapy in COVID-19 infected sick patients. We will collect up to 500 ml Convalescent Plasma
from the COVID-19 infected recovered patient after 14 days of clinical and radiological
recovery with two consecutive COVID-19 negative tests by PCR. We will further test the sample
from the collected plasma for COVID-19 specific antibodies and their titer. This plasma will
be frozen and sent to the treating center (MAMC). 200-600 ml of convalescent plasma will be
transfused to patients who fit the eligibility criteria and are randomized to the
convalescent plasma group. This will be done in severely sick patients. Data will be
collected for the benefit and adverse events related to convalescent plasma transfusion.
NCT04346446 COVID Drug: Convalescent Plasma Transfusion Other: Supportive Care Drug: Random Donor Plasma
Primary Outcomes
Measure: Proportion of patients remaining free of mechanical ventilation in both groups Time: Day 7
Secondary Outcomes
Measure: Mortality in both groups Time: Day 28
Measure: Improvement in Pa02/Fi02 ratio in both groups Time: Day 2
Measure: Improvement in Pa02/Fi02 ratio in both groups Time: Day 7
Measure: Improvement in SOFA score in both groups Time: Day 2
Measure: Improvement in SOFA score in both groups Time: Day 7
Measure: Duration of hospital Stay in both group. Time: Day 28
Measure: Duration of Intensive Care Unit stay in both groups. Time: Day 28
Measure: Requirements of Vasopressor in both groups. Time: Day 28
Measure: Days free of dialysis in both groups. Time: Day 28
No related HPO nodes (Using clinical trials)